Ultragenyx Pharmaceutical Stock Forecast

Stock Price Forecast

According to 21 analysts polled by S&P Global, Ultragenyx Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $26.25. The average 1-year stock price forecast is 63.04% higher than the current stock price, while the lowest is $16 (-0.62%) and the highest is $39 (+142.24%).

Price Target: $26.25 (+63.04%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$16	$26.25	$24	$39
Change	-0.62%	+63.04%	+49.07%	+142.24%

Analyst Ratings

The average analyst rating for Ultragenyx Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	12	12	12	13	8	8
Buy	5	5	5	5	2	2
Hold	2	2	2	2	10	11
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	19	19	19	20	20	21

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Allison Bratzel Piper Sandler	Piper Sandler	Buy Maintains $36	Buy	Maintains	$36	+123.60%	Oct 21, 2026
Joon Lee UBS	UBS	Hold Initiates $16	Hold	Initiates	$16	-0.62%	Oct 14, 2026
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $25	Buy	Reiterates	$25	+55.28%	Oct 14, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Hold Maintains $20	Hold	Maintains	$20	+24.22%	Oct 9, 2026
Luca Issi RBC Capital	RBC Capital	Hold Maintains $19	Hold	Maintains	$19	+18.01%	Oct 9, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

760.21M

from 673.00M

12.96%

from 673.00M

Revenue Next Year

997.05M

from 760.21M

31.15%

from 760.21M

EPS This Year

-4.08

from -5.83

EPS Next Year

0.23

from -4.08

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	351.41M	363.33M	434.00M	560.00M	673.00M	760.21M
Revenue Growth	29.66%	3.39%	19.45%	29.03%	20.18%	12.96%
Operating Income	-381.74M	-648.92M	-569.00M	-536.00M	-535.00M	-415.45M
Net Income	-454.03M	-707.42M	-607.00M	-569.00M	-575.00M	-390.49M
EPS	-	-	-	-	-5.83	-4.08
Free Cash Flow	-	-	-	-	-472.00M	346.00M
No. Analysts	-	-	-	-	-	19

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	903.1M
Avg	760.2M
Low	701.9M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	34.2%
Avg	13.0%
Low	4.3%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-1.18
Avg	-4.08
Low	-4.96

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-